All News

23 March 2007

MilleGen and LFB Sign Research Partnership Agreement to Develop New Generation of Therapeutic Monoclonal AntibodiesAntibodies

23 March 2007

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell’s ONCONASE(R)Antibodies

22 March 2007

Peregrine Pharmaceuticals Completes Patient Enrollment in Bavituximab Combination Therapy Trial in Advanced Cancer PatientsAntibodies

22 March 2007

Phase II/III pivotal study with trifunctional antibody removab(R) shows encouraging results in malignant ascites from various cancersAntibodies

22 March 2007

Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical TrialAntibodies

21 March 2007

Pain Therapeutics Cleared to Initiate Phase I Study in Metastatic MelanomaAntibodies

17 March 2007

Genmab in Research Cooperation with the Dahanca-GroupAntibodies

17 March 2007

Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer TreatmentAntibodies

17 March 2007

FDA Approves Alexion’s Soliris(TM) for All Patients With PNHAntibodies

13 March 2007

New Insights Into Novel Mechanisms of Action of Genmab’s HuMax-EGFrAntibodies

13 March 2007

Protherics to receive Â£10 million milestone from AstraZenecaAntibodies

13 March 2007

TopoTarget Executes Its Licensing Option for the Development of Zemab for Breast CancerAntibodies

13 March 2007

Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical EvaluationAntibodies

13 March 2007

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple SclerosisAntibodies

8 March 2007

MAT Biopharma Announced Today the Initiation of the Phase I/II Escalating Dose of Ferritarg P(R)Antibodies

7 March 2007

Kyowa Hakko Kogyo Co., Ltd. Licenses its in-house developed antibody KW-2871 targeting malignant melanoma to Life Science Pharmaceuticals in the US.Antibodies

1 March 2007

XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and DevelopmentAntibodies

28 February 2007

HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn’s DiseaseAntibodies

28 February 2007

EvoGenix and Vegenics announce collaborationAntibodies

28 February 2007

Vaccinex Announces Antibody Development And Commercialization Alliance In Multiple Sclerosis And OncologyAntibodies

28 February 2007

Cytogen Announces Initiation of Phase 1 Trial for Radiolabeled Antibody for the Treatment of Hormone-Refractory Prostate CancerAntibodies

27 February 2007

Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in JapanAntibodies

24 February 2007

Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancerAntibodies

23 February 2007

Significant Phase III Results with CIMZIA(TM) in Rheumatoid ArthritisAntibodies

23 February 2007

Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) AntibodyAntibodies

23 February 2007

New phase III study confirms positive outcome of Avastin in patients with advanced lung cancerAntibodies

15 February 2007

DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6(R) technology platformAntibodies

15 February 2007

Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C InfectionAntibodies

15 February 2007

Viventia Biotech provides update on cancer antibody clinical development programsAntibodies

14 February 2007

Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization AgreementAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Aflibercept (Eylea) Biosimilars Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins